Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ: WGS )

79.39 +2.47 (+3.21%)
Streaming Delayed Price Updated: 10:20 AM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 3 4 5 Next >
GeneDx Commends the States of Arizona and Florida for Adding Rapid Whole Genome Sequencing (rWGS) as a Covered Benefit for Medicaid Pediatric Patients
Eight state Medicaid programs now cover rWGS in the pediatric inpatient setting, with active bills in other states 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in Upcoming Investor Conferences in June
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations
Keynote session to highlight value of GeneDx genomic data and clinical insights to accelerate genetic neurodevelopmental disorder pipeline for Mahzi Therapeutics 
From GeneDx Holdings Corp.
Via GlobeNewswire
Recap: GeneDx Hldgs Q1 Earnings
Via Benzinga
Earnings Preview: GeneDx Hldgs
Via Benzinga
Why Shares of GeneDx Dropped Wednesday
The potential of a reverse split concerned investors. 
Via The Motley Fool
GeneDx Regains Compliance with Nasdaq Minimum Bid Price Requirement
From GeneDx Holdings Corp.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 199 companies reached new 52-week lows. 
Via Benzinga
GeneDx Holdings's Earnings: A Preview
Via Benzinga
GeneDx Reports First Quarter 2023 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
GeneDx Adds Buccal Swab as Non-Invasive Whole Genome Sequencing Sample Collection Option
New Option Enables Easier DNA Sample Collection from Biological Parents to Aid in Disease Diagnosis 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Clarification Regarding CUSIP Number for Public Warrant Holders
From GeneDx Holdings Corp.
Via GlobeNewswire
Why GeneDx Holdings Stock Lagged the Market Today
A financial-engineering move about to be made by the company is an indication of some deep and challenging problems. 
Via The Motley Fool
GeneDx Announces Reverse Stock Split
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Appoints Devin K. Schaffer, J.D., M.B.A, as General Counsel
From GeneDx Holdings Corp.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time for another dive into the biggest pre-market stock movers with all the hot topics traders need to know about on Friday! 
Via InvestorPlace
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. 
Via Benzinga
First Majestic Silver, Immatics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
From GeneDx Holdings Corp.
Via GlobeNewswire
The 7 Worst Stocks to Buy Now
With the market reeling from the banking crisis, even hardened gamblers should avoid these worst stocks to buy now. 
Via InvestorPlace
GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray
New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing’s role in shortening the diagnostic odyssey 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
Research illustrates company’s progress in working to end the diagnostic odyssey and includes data with implications for how care is delivered to patients beginning at birth 
From GeneDx Holdings Corp.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Windtree Therapeutics Inc (NASDAQ: WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous... 
Via Benzinga
GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback